Literature DB >> 3038012

Susceptibility of anaerobic bacteria to FCE 22101.

C E Nord, A Lindmark, I Person.   

Abstract

The activity of FCE 22101 against 675 strains of anaerobic bacteria was determined by an agar dilution method. Its activity was compared with those of benzylpenicillin, piperacillin, cefoxitin, imipenem, clindamycin, metronidazole, chloramphenicol, vancomycin, fusidic acid, and bacitracin. FCE 22101 and imipenem (MIC, less than or equal to 0.5 mg/liter) were the most active agents against the anaerobic strains tested, except against Clostridium difficile strains. On the basis of these results, FCE 22101 appears to be a promising antimicrobial agent for treatment of anaerobic infections, and further clinical investigations are indicated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038012      PMCID: PMC174847          DOI: 10.1128/AAC.31.5.831

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  Antibiotic susceptibility of anaerobic bacteria with special reference to Bacteroides fragilis.

Authors:  K Dornbusch; C E Nord; B Olsson-Liljeqvist
Journal:  Scand J Infect Dis Suppl       Date:  1979

Review 2.  Aspects on antibacterial treatment of anaerobic infections.

Authors:  F Nordbring; C E Nord
Journal:  Scand J Infect Dis Suppl       Date:  1982

3.  The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

  3 in total
  9 in total

1.  Susceptibility of Bacteroides non-fragilis and fusobacteria to amoxicillin, amoxicillin/clavulanate, ticarcillin, ticarcillin/clavulanate, cefoxitin, imipenem and metronidazole.

Authors:  M R Jacobs; S K Spangler; P C Appelbaum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

2.  Interaction of FCE 22101 with penicillin-binding proteins of Staphylococcus aureus.

Authors:  E A Tonin; R Fontana
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

3.  In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101.

Authors:  A L Barry; K E Aldridge; S D Allen; P C Fuchs; E H Gerlach; R N Jones; M A Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

4.  Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  Resistance of Peptostreptococcus spp. to macrolides and lincosamides: inducible and constitutive phenotypes.

Authors:  M Reig; A Moreno; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

6.  Clinical and bacteriological efficacy and tolerability of FCE 22891 in patients with exacerbations of chronic obstructive pulmonary disease.

Authors:  W G Boersma; S M Puister; R van Altena; H G de Vries-Hospers; M Molinari; G H Koëter
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

7.  The effect of FCE 22891, a new oral penem, on faecal flora anaerobes and their fermentation end products in patients with chronic obstructive pulmonary disease.

Authors:  G J Meijer-Severs; E van Santen; S M Puister; W G Boersma
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

8.  beta-Lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents.

Authors:  M R Jacobs; S K Spangler; P C Appelbaum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

9.  Comparison of Various Approaches to Translate Non-Linear Pharmacokinetics of Monoclonal Antibodies from Cynomolgus Monkey to Human.

Authors:  Renu Singh; Maria Moreno; Danica Stanimirovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-06-13       Impact factor: 2.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.